Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

Thalidomide Plus Chemotherapy Versus Chemotherapy Alone: A Phase II Study in Advanced Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02649101
• Other study ID #: ZCHBC-007
• Status: Recruiting
• Phase: Phase 2
• First received: December 13, 2015
• Last updated: January 5, 2016
• Start date: October 2015
• Est. completion date: October 2017

Study information

• Verified date: January 2016
• Source: Zhejiang Cancer Hospital
• Contact: lei lei, master
• Phone: +8613750802564
• Email: leilei1241[@]163.com
• Is FDA regulated: No
• Health authority: China: Health and Family Planning Commission of Zhejiang Province
• Study type: Interventional

Clinical Trial Summary

Sixty advanced breast cancer patients are planed to enrolled in this clinical trial. Forty patients are enrolled into thalidomide plus chemotherapy group. Twenty patients are enrolled into chemotherapy alone group. There is no restriction on chemotherapy regimen and lines.

Description:

The study compares the combination of thalidomide and chemotherapy with chemotherapy alone for the treatment of stage IV breast cancer. Efficacy and safety of the chemotherapy-thalidomide combination will be evaluated. Assessing the isolated effects of thalidomide in a setting where pre and post treatment serum specimens can be obtained will provide essential information about the mechanisms by which vascular endothelial growth factor(VEGF) inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of thalidomide on breast tumor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

1. inclusion criteria:

• Women >/= 18 and < 65 years of age .

• Histologically or cytologically confirmed breast cancer with evidence of metastatic disease. (Note: the participant must be recovered from any clinically significant toxicity thereof last therapy.)

• ECOG performance status 0-2.

• Adequate bone marrow, kidney and liver function.

• ER/PR breast cancer positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.

2. exclusion criteria:

• Prior treatment with thalidomide.

• Patients with HER2 positive disease.

• Untreated and/or uncontrolled brain metastases.

• Prior malignancy unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, DCIS or stage I grade 1 endometrial cancer allowed.

• Known HIV (Human Immunodeficiency Virus) infection.

• Pregnant or breast-feeding women.

• Bilateral invasive breast cancer.

• Cardiac and thrombotic disease or risk for same as judged by Investigator.

• Other serious illness or medical conditions such as (partial list- review with Investigator) history of significant neurologic or psychiatric disorders that would prohibit the understanding and giving of informed consent, active uncontrolled infection, active peptic ulcer, unstable diabetes mellitus or subjects with symptomatic, intrinsic lung disease resulting in dyspnea at rest.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Thalidomide
Thalidomide tablet 100mg qn po.
• Physician's choice chemotherapy
Investigators will declare no constraint of regimens.

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival(PFS)	PFS is defined as the months that from the anticipation of the clinical-trial to the progress of breast cancer.	Change from Baseline RECIST at 6 months was assessed every 6 weeks up to 24 weeks. Data collection is from date of randomization until the date of first documented progression assessed up to 6 months.	No
Secondary	Overall survival(OS)	OS is defined as the months that from the anticipation of the clinical-trial to the death of patients.	Survival assessed every 8 weeks up to 100 months following objective disease progression. Data collection is from date of randomization until the date of death from any cause, assessed up to 100 months.	No